Assessment of B2-Microglobulin Analysis for Renal Insufficiency in Iraqi β-Thalassemia Major Patients
DOI:
https://doi.org/10.23851/mjs.v35i3.1391Keywords:
β-thalassemia major, B2-microglobulin, Ferritin, B.Urea, CreatinineAbstract
Background: Beta-thalassemia is the most prevalent genetic hemoglobin apathy in the world. It is caused by a reduction or absence of beta-globin chain production, which is typically a portion of adult hemoglobin (HbA, which is α2β2). This genetic anomaly will lead to a rapid erythrocyte turnover, severe anemia, and compensatory ineffective erythropoiesis. The purpose of the current research is to reveal diagnostic, and predictive biomarkers that can be performed to detect the decline in renal function in β-thalassemia major patients with early stage renal impairment with high sensitivity and specificity, ascertain changes in B2-microglobulin as a biomarker in β-thalassemia patient. Objective: The samples were collected from Karama Hospital-Genetic Hematology Center/Baghdad during the period from the 1st of September 2022 until the 1st of January 2023. Methods: The patient group consisted of 45 patients with β-thalassemia major with repeated blood transfusion and the control group consisted of 45 individuals who seemed to be healthy. Age ranged between (18-35) years (for patients and control). The serum samples were used to measure biochemical parameters, S.Creatinine, blood urea, and Urine B2-microglobulin were measured from urine samples. B2-microglobulin level in Urine was estimated by Sandwich enzyme-linked immunosorbent assay (ELISA) technique, while serum Blood Urea and Serum Creatinine concentration were calculated by Colorimetric Kit by Spectrophotometer method, and Ferritin level in blood was estimated by BioMrieux Mini Vidas. Results: The statistical examination was carried out using SPSS software. B2-microglobulin biomarkers in the thalassemia Patient group were significantly higher than those in the control group (p<0.001). While serum ferritin, B.Urea and S.Cr increased in patient groups compared to the control group (p<0. 005). Conclusions: All parameters included in this study are significantly higher in β-thalassemia patients than in healthy subjects. Renal hemosiderosis and asymptomatic renal dysfunction are prevalent among β-thalassemia major patients with repeated blood transfusions, which are not found in routine renal investigations.
Downloads
References
O. M. Baqer and A. K. Al-Humairi, "Knowledge, attitude, and practice of junior doctors about thalassemia in babylon province," Medical Journal of Babylon, vol. 19, no. 2, p. 162, 2022.
P. Jain, N. Marwah, N. Dalal, R. Pawar, M. Gill, and S. Kumar, "Delta beta thalassemia, a rare hemoglobin variant: An experience from nodal centre in north indian state," Journal of Applied Hematology, vol. 13, no. 1, p. 1, 2022.
V. Marakala, "Neutrophil gelatinase-associated lipocalin (ngal) in kidney injury: A systematic review," Clinica chimica acta, vol. 536, pp. 135-141, 2022, issn: 0009-8981.
M. Y. Bakheet, B. R. Mohamed, M. A. Ghany, and Z. A. Abd Elhameed, "Serum neutrophil gelatinase-associated lipocalin as a predictor of acute kidney injury in patients with coronary artery disease," Journal of Current Medical Research and Practice, vol. 7, no. 1, p. 50, 2022.
E. V. Schrezenmeier, J. Barasch, K. Budde, T. Westhoff, and K. M. Schmidt-Ott, "Biomarkers in acute kidney injury: Pathophysiological basis and clinical performance," Acta physiologica, vol. 219, no. 3, pp. 556-574, 2017.
F. Koohi, T. Kazemi, and E. Miri-Moghaddam, "Cardiac complications and iron overload in beta thalassemia major patients: A systematic review and meta-analysis," Annals of hematology, vol. 98, no. 6, pp. 1323-1331, 2019.
M. H. Ahmed, M. S. Ghatge, and M. K. Safo, Hemoglobin: Structure, function and allostery. 2020, pp. 345-382.
A. J. Marengo-Rowe, "Structure-function relations of human hemoglobins," Baylor University Medical Center Proceedings, vol. 19, no. 3, pp. 239-245, 2006.
A. Makis, E. Voskaridou, I. Papassotiriou, and E. Hatzimichael, "Novel therapeutic advances in β-thalassemia," Biology (Basel), vol. 10, no. 6, p. 546, 2021.
N. Li, P. An, J. Wang, T. Zhang, X. Qing, B. Wu, L. Sun, X. Ding, L. Niu, Z. Xie, M. Zhang, X. Guo, X. Chen, T. Cai, J. Luo, F. Wang, and F. Yang, "Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia," Iscience, vol. 25, no. 4, p. 104 091, 2022.
M. Y. K. Zeid, H. M. A. Hassab, D. N. Younan, and O. Arab, "Study of the effect of different iron-chelating agents on early renal glomerular and tubular function markers in children with beta-thalassemia," Alexandria J. Pediatr., vol. 32, no. 3, p. 116, 2019.
M. Hamdy, I. Shaheen, Z. M. El-Gammal, and Y. M. Ramadan, "Detection of renal insufficiency in a cohort of patients with beta-thalassemia major using cystatin-c," Journal of Pediatric Hematology/Oncology, 2022.
S. Qun, F. Hu, G. Wang, J. Wu, Q. Tang, J. Zhang, Z. Chen, X. Wang, Q. Liu, and W. Ge, "Serum beta2-microglobulin levels are highly associated with the risk of acute ischemic stroke," Scientific Reports, vol. 9, no. 1, pp. 1-8, 2019.
H. Wang, B. Liu, and J. Wei, "Beta2-microglobulin (b2m) in cancer immunotherapies: Biological function, resis tance and remedy," Cancer letters, vol. 517, pp. 96-104, 2021.
N. H. Dung, N. T. Kien, N. T. T. Hai, P. T. Cuong, N. T. T. Huong, D. B. Q. Quyen, N. M. Tuan, D. M. Ha, T. Q. Kien, N. T. T. Dung, P. Q. Toan, H. T. Vinh, T. Usui, and L. V. Thang, "Measuring serum beta2-microglobulin to predict long-term mortality in hemodialysis patients using low-flux dialyzer reuse," Therapeutics and Clinical Risk Management, pp. 839-846, 2019.
A. G. Kaçar, İ. Şilfeler, A. Kacar, F. Pekun, E. Türkkan, and E. Adal, "Levels of beta-2 microglobulin and cystatin c in beta thalassemia major patients," Journal of Clinical and Analytical Medicine, vol. 6, no. 3, pp. 269-273, 2015.
M. H. Rosner, T. Reis, F. Husain-Syed, R. Vanholder, C. Hutchison, P. Stenvinkel, P. J. Blankestijn, M. Cozzolino, L. Juillard, K. Kashani, M. Kaushik, H. Kawanishi, Z. Massy, T. L. Sirich, L. Zuo, and C. Ronco, "Classification of uremic toxins and their role in kidney failure," Clinical Journal of the American Society of Nephrology, vol. 16, no. 12, pp. 1918-1928, 2021.
R. Wang, H. Hu, S. Hu, H. He, and H. Shui, "β2-microglobulin is an independent indicator of acute kidney injury and outcomes in patients with intracerebral hemorrhage," Medicine (Baltimore), vol. 99, no. 8, 2020.
A. O. Eguvbe, M. U. Nwagu, E. S. Idogun, and A. A. Akande, "The role of urine albumin creatinine ratio and serum β2 microglobulin as biomarkers of chronic kidney disease," Universa Medicina, vol. 38, no. 3, pp. 172-178, 2019.
P. A. Keown, "Predicting long-term outcome in renal transplantation," Kidney international, vol. 84, no. 4, pp. 650-652, 2013.
B. Stephenson, G. Chertow, Y. Yang, and D. Rosenbaum, "Puk2 hospitalization in patients receiving maintenance dialysis with hyperphosphatemia randomized to tenapanor or sevelamer," Value in Health, vol. 24, S234, 2021.
M. Althubiti, M. Elzubier, G. S. Alotaibi, M. A. Althubaiti, H. H. Alsadi, Z. A. Alhazmi, F. Alghamdi, M. Z. El-Readi, R. Almaimani, and A. Babakr, "Beta 2 microglobulin correlates with oxidative stress in elderly," Experimental Gerontology, vol. 150, p. 111 359, 2021.
E. Uzun, Y. I. Balcı, S. Yüksel, Y. Z. Aral, H. Aybek, and B. Akdağ, "Glomerular and tubular functions in children with different forms of beta thalassemia," Renal failure, vol. 37, no. 9, pp. 1414-1418, 2015.
M. Economou, N. Printza, A. Teli, V. Tzimouli, I. Tsatra, F. Papachristou, and M. Athanassiou-Metaxa, "Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox," Acta haematologica, vol. 123, no. 3, pp. 148-152, 2010.
V. Şen, A. Ece, Ü. Uluca, M. Söker, A. Güneş, İ. Kaplan, İ. Tan, S. Yel, N. Mete, and C. Sahin, "Urinary early kidney injury molecules in children with beta-thalassemia major," Renal failure, vol. 37, no. 4, pp. 607-613, 2015.
F. Shah, K. Huey, S. Deshpande, M. Turner, M. Chitnis, E. Schiller, A. Yucel, L. Moro Bueno, and E. N. Oliva, "Relationship between serum ferritin and outcomes in β-thalassemia: A systematic literature review," Journal of Clinical Medicine, vol. 11, no. 15, p. 4448, 2022.
A. Meloni, L. Barbuto, L. Pistoia, V. Positano, S. Renne, G. Peritore, P. Fina, A. Spasiano, M. Allò, and G.Messina, "Frequency, pattern, and associations of renal iron accumulation in sickle/β-thalassemia patients," Annals of Hematology, vol. 101, no. 9, pp. 1941-1950, 2022.
S. Afshan, M. H. Parisa, A. Shahram, A. Azita, and M. Hashemieh, "Renal iron load estimation in thalassemia patients using t2* magnetic resonance imaging," International Journal of Medical Research & Health Sciences, vol. 8, pp. 182-189, 2019.
A. Spasiano, A. Meloni, S. Costantini, E. Quaia, F. Cademartiri, P. Cinque, A. Pepe, and P. Ricchi, "Setting for 'normal' serum ferritin levels in patients with transfusion-dependent thalassemia: Our current strategy," Journal of Clinical Medicine, vol. 10, no. 24, p. 5985, 2021.
Z. M. Dimitrijevic, S. S. Salinger-Martinovic, R. J. Jankovic, and B. P. Mitic, "Elevated serum ferritin levels are predictive of renal function recovery among patients with acute kidney injury," The Tohoku Journal of Experimental Medicine, vol. 248, no. 2, pp. 63-71, 2019.
M. R. El-Shanshory, L. M. Sherief, H. M. Hassab, S. M. Ragab, S. Yahia, A. K. Mansour, A. S. Ahmed, S. H. Abdou, A. M. Helmy, M. M. Watany, A. M. Gad ALllah, M. A. Guindy, Z. I. Mourad, M. A. Soliman, R. M. El-Farahaty, F. El-Dahtory, A. Darwish, S. A. Elmabood, I. A. Kabbash, and S. M. Saied, "Prevalence of iron deficiency anemia and beta thalassemia carriers among relatives of beta thalassemia patients in nile delta region, egypt: A multicenter study," Journal of the Egyptian Public Health Association, vol. 96, no. 1, pp. 1-8, 2021.
Downloads
Key Dates
Received
Revised
Accepted
Published
Data Availability Statement
Data is available in the article.
Issue
Section
License
Copyright (c) 2024 Estabraq Salman Alwan, Thana Mohammed Juda, Liqaa M. Majed
This work is licensed under a Creative Commons Attribution 4.0 International License.
(Starting May 5, 2024) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
How to Cite
